Prelude Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-7,036
| Closed | -$1.2M | – | 1405 |
|
|
2025
Q4 | $1.2M | Buy |
+7,036
| New | +$1.08M | 0.09% | 256 |
|
|
2025
Q2 | – | Sell |
-1,615
| Closed | -$201K | – | 1173 |
|
|
2025
Q1 | $201K | Buy |
+1,615
| New | +$211K | 0.02% | 947 |
|
|
2022
Q4 | – | Sell |
-3,277
| Closed | -$437K | – | 1465 |
|
|
2022
Q3 | $437K | Buy |
+3,277
| New | +$498K | 0.02% | 703 |
|
|
2021
Q1 | – | Sell |
-4,074
| Closed | -$672K | – | 1682 |
|
|
2020
Q4 | $672K | Buy |
+4,074
| New | +$607K | 0.02% | 611 |
|
|
2020
Q1 | – | Sell |
-654
| Closed | -$98K | – | 1727 |
|
|
2019
Q4 | $98K | Buy |
+654
| New | +$89K | ﹤0.01% | 1113 |
|
|
2019
Q3 | – | Sell |
-2,230
| Closed | -$318K | – | 1875 |
|
|
2019
Q2 | $318K | Buy |
2,230
+2,171
| +3,680% | +$292K | 0.02% | 596 |
|
|
2019
Q1 | $8K | Sell |
59
-1,168
| -95% | -$152K | ﹤0.01% | 1523 |
|
|
2018
Q4 | $152K | Sell |
1,227
-13,848
| -92% | -$2.05M | 0.01% | 815 |
|
|
2018
Q3 | $2.54M | Sell |
15,075
-12,318
| -45% | -$2.12M | 0.15% | 141 |
|
|
2018
Q2 | $4.72M | Buy |
27,393
+282
| +1% | +$46.1K | 0.3% | 54 |
|
|
2018
Q1 | $4.09M | Sell |
27,111
-255
| -0.9% | -$37.4K | 0.3% | 53 |
|
|
2017
Q4 | $3.69M | Sell |
27,366
-2,946
| -10% | -$409K | 0.3% | 66 |
|
|
2017
Q3 | $4.43M | Buy |
30,312
+13,553
| +81% | +$2.05M | 0.4% | 49 |
|
|
2017
Q2 | $2.61M | Buy |
16,759
+645
| +4% | +$98.6K | 0.25% | 86 |
|
|
2017
Q1 | $2.34M | Sell |
16,114
-1,475
| -8% | -$192K | 0.22% | 106 |
|
|
2016
Q4 | $1.92M | Buy |
17,589
+6,824
| +63% | +$760K | 0.23% | 120 |
|
|
2016
Q3 | $1.31M | Buy |
10,765
+7,690
| +250% | +$1.04M | 0.14% | 166 |
|
|
2016
Q2 | $435K | Buy |
3,075
+955
| +45% | +$141K | 0.06% | 307 |
|
|
2016
Q1 | $277K | Buy |
2,120
+380
| +22% | +$47.3K | 0.04% | 435 |
|
|
2015
Q4 | $245K | Sell |
1,740
-275
| -14% | -$38.1K | 0.04% | 471 |
|
|
2015
Q3 | $268K | Sell |
2,015
-140
| -6% | -$24.1K | 0.04% | 475 |
|
|
2015
Q2 | $379K | Sell |
2,155
-1,020
| -32% | -$183K | 0.05% | 379 |
|
|
2015
Q1 | $549K | Buy |
3,175
+1,475
| +87% | +$253K | 0.08% | 308 |
|
|
2014
Q4 | $278K | Buy |
1,700
+200
| +13% | +$33.2K | 0.04% | 527 |
|
|
2014
Q3 | $241K | Sell |
1,500
-200
| -12% | -$30.7K | 0.03% | 636 |
|
|
2014
Q2 | $250K | Hold |
1,700
| – | – | 0.03% | 656 |
|
|
2014
Q1 | $236K | Sell |
1,700
-1,600
| -48% | -$241K | 0.03% | 672 |
|
|
2013
Q4 | $418K | Buy |
3,300
+300
| +10% | +$31K | 0.07% | 407 |
|
|
2013
Q3 | $276K | Buy |
3,000
+1,500
| +100% | +$121K | 0.04% | 442 |
|
|
2013
Q2 | $103K | Buy |
+1,500
| New | +$91.7K | 0.02% | 632 |
|
Other funds holding JAZZ
VPM
VCM
EC
Prelude Capital Management's JAZZ Position: Q1 2026 in Review
Prelude Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 7,036 shares — an estimated $1.2M sold.
Prelude Capital Management first reported a position in JAZZ in Q2 2013 and held it in 30 quarters. The position peaked at $4.72M in Q2 2018. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Prelude Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Prelude Capital Management sold 7,036 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.2M.
- Prelude Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Prelude Capital Management's Jazz Pharmaceuticals position peaked at $4.72M in Q2 2018.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.